[144] Avidity Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Avidity Biosciences (RNA) filing a Form 144 notifies the proposed sale of 20,000 common shares held by a person for whose account the sale is to be made. The shares were acquired on 09/11/2025 by exercise of stock options from the issuer and paid for in cash on the same date. The aggregate market value of the proposed sale is reported as $928,000.00 and the issuer's outstanding shares are listed as 128,653,337. The sale is expected to occur on or about 09/11/2025 through NASDAQ via Morgan Stanley Smith Barney LLC Executive Financial Services. The filing states there were no securities sold by the person in the past three months.

Insights

Securities Analyst

TL;DR: Routine insider sale notice for 20,000 shares following option exercise; limited immediate market impact.

The Form 144 documents a proposed sale by a person who acquired 20,000 common shares via option exercise on 09/11/2025 and intends to sell on or about that date through Morgan Stanley Smith Barney LLC. The filing includes the aggregate market value of $928,000 and reports no sales in the prior three months. This is a standard Rule 144 disclosure showing an insider meeting the required notice procedures before offering shares for sale.

Corporate Governance Expert

TL;DR: Compliance-oriented disclosure; confirms exercise and planned sale but provides limited governance implications.

The notice indicates the securities were acquired from the issuer by exercise of stock options and paid in cash on 09/11/2025, with the seller representing no undisclosed material adverse information. The form lists the broker and exchange, fulfilling procedural requirements under Rule 144. No past three-month sales are reported, which simplifies aggregation rules. The filing is procedural and does not, by itself, indicate changes in management or control.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	928000.00	128653337	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/11/2025	Exercise of Stock Options	Issuer			20000	09/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Avidity Biosciences' (RNA) Form 144 report?

The Form 144 reports a proposed sale of 20,000 common shares with an aggregate market value of $928,000.00, to be sold on or about 09/11/2025 on NASDAQ.

How were the Avidity (RNA) shares being sold acquired?

The shares were acquired on 09/11/2025 by exercise of stock options from the issuer and paid for in cash on the same date.

Through which broker will the RNA shares be sold?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the proposed sale.

Did the seller of RNA shares sell any securities in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What is the issuer's reported number of outstanding shares?

The filing reports 128,653,337 shares outstanding for the issuer.